1. LMK-235 suppresses osteoclastogenesis and promotes osteoblastogenesis by inhibiting HDAC4
- Author
-
Chongwei Chen, Yue Li, Teng Feng, Xinping Chen, Chengwei Li, Lu Li, Mengbo Zhu, Yaqiong Chang, and Shaowei Wang
- Subjects
LMK-235 ,Osteoclast ,Osteoblast ,HDAC4 ,Osteolysis ,Medicine ,Science - Abstract
Abstract Osteoblasts and osteoclasts play an important role in maintaining the structural integrity of bone tissue, in which osteoclasts degrade bone structure and osteoblasts restore bone tissue. The imbalance of osteoblast and osteoclast function can lead to many bone-related diseases, such as osteoporosis and inflammatory osteolysis. The drug that can both promote bone formation and inhibit bone loss will be able to treat those diseases. In this study, it was found that LMK-235, an selective HDAC4/5 inhibitor, inhibited the differentiation and maturation of osteoclasts by regulating NF-κB and p-Smad2/3 signaling pathways via inhibition of HDAC4. At the same time, we found that LMK-235 promoted osteoblast mineralization by upregulating Runx2 expression via inhibition of HDAC4. In vivo, LMK-235 was able to alleviate lipopolysaccharide (LPS)-induced calvarial osteolysis and promote the repair of bone defects. Taken together, LMK-235 suppresses osteoclast differentiation and promotes osteoblast formation by inhibiting HDAC4. This may provide a valuable treatment for bone diseases caused by abnormal osteoclast bone resorption and osteoblast bone regeneration.
- Published
- 2024
- Full Text
- View/download PDF